Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial – Eli Lilly
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC People Are Already Taking This Unapproved New Weight-Loss Drug WIRED Lilly’s obesity pill largely maintains weight lost on injectable […]
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly – CNBC
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly CNBC Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Yahoo Finance A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound. MarketWatch […]
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound – CNBC
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly People Are Already Taking This Unapproved New Weight-Loss Drug WIRED Major Weight Loss and Knee-Pain Relief Seen With New […]
Eli Lilly Scores Another Major Win: Time to Buy?
Can anyone stop Eli Lilly (NYSE: LLY)? The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many other drugmakers are hot on its tail, Lilly has consistently demonstrated that, in addition to having the top approved product in this category, it also has pipeline candidates that outshine […]
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one…
Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?
Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, is likely a factor.
Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Eli Lilly’s experimental obesity pill allowed patients who had lost weight on injected GLP-1-based drugs to keep most of the weight off for another year, according to data from a Phase 3 trial released Thursday …
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved…
Mitochondrial control of fuel switching via carnitine biosynthesis
Metabolic adaptation to environmental changes, such as fasting and cold exposure, involves a dynamic shift in fuel utilization from glucose to fatty acid oxidation, a process that relies on carnitine-mediated fatty acid oxidation in mitochondria. While dietary sources of animal origin (e.g., red meat) contribute to the carnitine pool, de novo carnitine synthesis from trimethyllysine […]
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.